Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Inotiv emerges from chapter 11
We advised an ad hoc group of first-lien lenders in connection with Inotiv’s chapter 11 proceedings
Financing for Bridgepoint acquisition of GBA Group
We are advising the lenders on the transaction
REGENXBIO $115 million equity offering
We advised the joint book-running managers and underwriters on the offering
Ascentage Pharma $200 million at-the-market offering
We advised the sales agents on the offering
GenFleet Therapeutics HK$471.8 million placement of new H shares
We advised GenFleet Therapeutics on the placement
Clarivate sale of Life Sciences & Healthcare segment to Altaris
We are advising Clarivate on the transaction
Alebund Pharmaceuticals HK$1.28 billion IPO
We advised Alebund Pharmaceuticals on its IPO and HKEX listing
Talawar Therapeutics $225 million PIPE financing and de-SPAC transaction
We advised the placement agents on the transaction
NeoGenomics $316.25 million convertible senior notes offering
We advised the initial purchasers on the offering
SOPHiA GENETICS $57.5 million follow-on offering
We advised SOPHiA GENETICS on the offering